StreetInsider.com News Articles

Jefferies Reiterates Buy Rating on Viking Therapeutic (VKTX): "VKTX is in an execution mode this year"

Thu, 12 Mar 2026 12:48:17 -0400

Jefferies analyst Roger Song reiterated a Buy rating and $101.00 price target on Viking Therapeutic (NASDAQ: VKTX)

The analyst commented, "We hosted VKTX in Miami for detailed discussion across pipeline/key drivers/ upcoming catalysts... VKTX is in an execution mode this year with two main value drivers that delivered best-in-class profile in respective categories, both in/heading into Ph3, fast-tracking to potential approval/well positioned for commercial discussion. The near-term focus is centered around clinical execution through subq Ph3 while preparing for oral Ph3 in 3Q26 and waiting for maintenance data in mid'26 to potentially add another layer of upside in informing RW use

Form 4 Viking Therapeutics, For: Mar 10 Filed by: Aubuchon Neil William

Tue, 10 Mar 2026 18:21:00 -0400

si-local-file:///var/storage/secattach/20260310/26141036.html

Form 4 Viking Therapeutics, For: Mar 10 Filed by: Aubuchon Neil William

Tue, 10 Mar 2026 18:21:00 -0400

si-local-file:///var/storage/secattach/20260310/26141036.html

Viking Therapeutics to Participate at Upcoming Investor Conferences

Thu, 05 Mar 2026 16:03:00 -0400

SAN DIEGO, March 5, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at multiple upcoming investor conferences.

Viking Therapeutics to Participate at Upcoming Investor Conferences

Thu, 05 Mar 2026 16:03:00 -0400

Viking Therapeutics to Participate at Upcoming Investor Conferences

Thu, 05 Mar 2026 16:03:00 -0400

Viking Therapeutics to Participate at Upcoming Investor Conferences

Thu, 05 Mar 2026 16:03:00 -0400

Truist on Viking Therapeutic (VKTX): 'Riding High On A Winning (GLP+GIP) Combination As Commercial Strategy Takes Shape'

Wed, 04 Mar 2026 14:13:55 -0400

Truist Securities analyst Joon Lee reiterated a Buy rating and $75.00 price target on Viking Therapeutic (NASDAQ: VKTX).

The analyst comments "We hosted VKTX mgmnt for NDR. The mood was upbeat as VK2735 was riding high on a winning combo of GLP+GIP as demonstrated by the recent REDEFINE4 toplined by NOVO. In this backdrop, mgmnt is executing on ongoing and forthcoming Ph3 programs for both SQ & oral VK2735. Offering of SQ and oral as well as monthly maintenance regimen of VK2735 could offer a comprehensive "closed-loop obesity ecosystem" with a commercial edge. Bottom line, VKTX is marching towards what could

Viking Therapeutic (VKTX) PT Lowered to $99 at Morgan Stanley

Thu, 12 Feb 2026 08:42:47 -0400

Morgan Stanley analyst Michael E Ulz lowered the price target on Viking Therapeutic (NASDAQ: VKTX) to $99.00 (from $102.00) while maintaining a Overweight rating.

Viking Therapeutic (VKTX) PT Lowered to $118 at Raymond James

Thu, 12 Feb 2026 06:48:51 -0400

Raymond James analyst Steve Seedhouse lowered the price target on Viking Therapeutic (NASDAQ: VKTX) to $118.00 (from $122.00) while maintaining a Strong Buy rating.

The analyst comments "We remain Strong Buy rated on Viking Therapeutics (VKTX) following 4Q25 earnings, largely driven by our positive outlook for Viking’s late-stage clinical subQ and oral VK2735 programs in the obesity space, as well as for its new amylin agonist expected to move into clinical studies later this year. Most incremental in this update, VKTX announced it expects topline data from its maintenance study and initiation of the Phase 3 program for oral VK2735 in

Viking Therapeutic (VKTX) PT Lowered to $118 at Raymond James

Thu, 12 Feb 2026 06:48:51 -0400

Raymond James analyst Steve Seedhouse lowered the price target on Viking Therapeutic (NASDAQ: VKTX) to $118.00 (from $122.00) while maintaining a Strong Buy rating.

Laidlaw Reiterates Buy Rating on Viking Therapeutic (VKTX)

Thu, 12 Feb 2026 02:45:04 -0400

Laidlaw analyst Yale Jen reiterated a Buy rating and $110.00 price target on Viking Therapeutic (NASDAQ: VKTX)

The analyst comments: "VKTX reported 4Q25 financial results and corporate updates today after the close. Our take is that VKTX has provided clearer pathways for a more comprehensive VK2735 in obesity advancement on many fronts. Specifically, in addition to the completion and the later data readout of subQ VK2735 VANQUISH studies, oral VK2735 is expected to enter Phase III study in 2H26 and we estimate topline readout possibly in 2028. The potential to incorporate maintenance regimen(s) as a treatment option could also add more

Form 10-K Viking Therapeutics, For: Dec 31

Wed, 11 Feb 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20260211/25984802.html

Form 10-K Viking Therapeutics, For: Dec 31

Wed, 11 Feb 2026 17:26:00 -0400

si-local-file:///var/storage/secattach/20260211/25984802.html

Viking Therapeutics (VKTX) Misses Q4 EPS by 48c

Wed, 11 Feb 2026 16:35:51 -0400

Viking Therapeutics (NASDAQ: VKTX) reported Q4 EPS of ($1.38), $0.48 worse than the analyst estimate of ($0.90).

For earnings history and earnings-related data on Viking Therapeutics (VKTX) click here.

Viking Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

Wed, 11 Feb 2026 16:16:00 -0400